Bicocca Open Archive

Logo unimib boa
STRAZZABOSCO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.510
AS - Asia 15.020
EU - Europa 10.968
SA - Sud America 2.080
AF - Africa 335
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 34
Totale 56.982
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.885
SG - Singapore 5.318
CN - Cina 3.426
HK - Hong Kong 2.132
VN - Vietnam 1.984
RU - Federazione Russa 1.930
SE - Svezia 1.635
BR - Brasile 1.557
IT - Italia 1.441
DE - Germania 1.351
IE - Irlanda 1.251
UA - Ucraina 1.151
GB - Regno Unito 673
FR - Francia 471
CA - Canada 461
IN - India 443
FI - Finlandia 381
KR - Corea 317
BD - Bangladesh 217
AR - Argentina 202
TR - Turchia 190
IQ - Iraq 181
AT - Austria 121
ZA - Sudafrica 118
NL - Olanda 108
DK - Danimarca 106
ID - Indonesia 104
MX - Messico 104
PK - Pakistan 104
JP - Giappone 100
SA - Arabia Saudita 80
EC - Ecuador 76
ES - Italia 76
CO - Colombia 70
PH - Filippine 65
PL - Polonia 58
UZ - Uzbekistan 56
VE - Venezuela 56
MA - Marocco 51
BE - Belgio 46
CL - Cile 42
KE - Kenya 30
MY - Malesia 29
JO - Giordania 28
PY - Paraguay 28
BG - Bulgaria 27
EU - Europa 27
CZ - Repubblica Ceca 26
TW - Taiwan 26
AU - Australia 24
IR - Iran 23
TN - Tunisia 23
AE - Emirati Arabi Uniti 22
NP - Nepal 22
ET - Etiopia 21
DZ - Algeria 19
EG - Egitto 19
PE - Perù 19
AZ - Azerbaigian 18
JM - Giamaica 17
RO - Romania 17
UY - Uruguay 17
OM - Oman 16
CH - Svizzera 15
IL - Israele 14
LT - Lituania 14
PS - Palestinian Territory 14
TH - Thailandia 14
KZ - Kazakistan 13
BO - Bolivia 10
SN - Senegal 10
NZ - Nuova Zelanda 9
DO - Repubblica Dominicana 8
LB - Libano 8
MD - Moldavia 8
NO - Norvegia 8
RS - Serbia 8
BH - Bahrain 7
BY - Bielorussia 7
CR - Costa Rica 7
HU - Ungheria 7
KG - Kirghizistan 7
KW - Kuwait 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
GA - Gabon 6
MN - Mongolia 6
AL - Albania 5
GE - Georgia 5
GR - Grecia 5
GT - Guatemala 5
HN - Honduras 5
MM - Myanmar 5
NI - Nicaragua 5
SC - Seychelles 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
PA - Panama 4
AM - Armenia 3
AO - Angola 3
Totale 56.916
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.259
Singapore 3.032
Woodbridge 2.789
Ashburn 2.511
Fairfield 2.114
Hong Kong 2.092
Houston 1.911
Chandler 1.335
Jacksonville 1.215
Dublin 1.214
San Jose 1.087
Wilmington 1.001
Seattle 881
Frankfurt am Main 852
Cambridge 769
New York 661
Ho Chi Minh City 581
Dearborn 556
Princeton 534
Beijing 470
Hanoi 452
Santa Clara 450
Hefei 435
The Dalles 432
Chicago 427
Milan 414
Dallas 328
Los Angeles 308
Nanjing 293
Seoul 291
Lauterbourg 249
Lawrence 228
Altamura 204
Lachine 197
Shanghai 194
Council Bluffs 176
Helsinki 146
Buffalo 144
São Paulo 137
Moscow 134
San Diego 129
Boardman 123
Guangzhou 114
Vienna 89
Shenyang 88
Da Nang 86
Toronto 85
Orem 80
Rome 78
Andover 76
Baghdad 75
Nanchang 75
Changsha 71
Tokyo 67
Ottawa 64
Hebei 63
London 63
Haiphong 62
Falls Church 57
Rio de Janeiro 57
Tianjin 57
Hangzhou 56
Jiaxing 50
Columbus 49
Johannesburg 49
Norwalk 49
Dong Ket 47
Munich 47
Chennai 46
Philadelphia 46
Brooklyn 45
Fremont 45
Jakarta 45
Mountain View 45
Jinan 44
Montreal 44
Tashkent 42
Nuremberg 41
Salt Lake City 41
Warsaw 41
Boston 40
Dhaka 40
Zhengzhou 38
Brasília 36
Brussels 36
Huizen 36
Pune 36
Hải Dương 35
Kunming 35
Belo Horizonte 32
Elk Grove Village 32
Can Tho 31
Lissone 29
Manchester 29
Mexico City 29
Phoenix 29
Redmond 29
Riyadh 29
Denver 28
Guayaquil 27
Totale 37.690
Salva come PNG Salva come JPEG
Nome #
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma 663
Impact of multidisciplinary team approach to liver tumors: 5-Years experience 508
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 476
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 440
JNK SIGNALING ACTIVATED BY PLATELET-DERIVED GROWTH FACTOR D (PDGF-D) STIMULATES SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C) BY CANCER-ASSOCIATED FIBROBLASTS TO PROMOTE LYMPHANGIOGENESIS AND EARLY METASTATIZATION IN CHOLANGIOCARCINOMA 423
Resveratrol impairs glioma stem cells proliferation and motility by modulating the wnt signaling pathway 378
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 376
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma 373
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 329
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 323
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study 317
Health related quality of life in chronic liver diseases 313
Long term outcome of acute pancreatitis in Italy: Results of a multicentre study 308
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 306
Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation 303
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions 303
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 302
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 299
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 296
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 295
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 289
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice 288
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 288
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 287
Effect of Silibinin on biliary lipid composition. Experimental and clinical study 284
The impact of liver disease on the health-related quality of life 284
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 277
Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma 276
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 275
Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium 274
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 273
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 273
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 271
Subcutaneous insulin infusion (CSII) in italy: The third national survey [La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale] 270
Cholangiocyte biology as relevant to cystic liver diseases 269
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 269
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice 268
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 268
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 267
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 264
Health Related Quality of Life in the Major Liver Conditions 263
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness 261
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. 260
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 260
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 260
The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity 259
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 259
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 257
Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development 256
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 252
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the " Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 251
Liver-allocation policies for patients affected by HCC in Europe 251
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice 250
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 249
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4NF-κB-mediated inflammatory response in mice 248
Difference in health related quality of life of chronic liver diseases and general population 248
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? 247
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. 246
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 246
pka-dependent p-ser- 675 β-catenin phosphorylation increases cholangiocyte motility in pkhd1del4/del4 mice, a model of fibropolycystic liver diseases caused by defective fibrocystin function 246
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 246
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 246
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 245
Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "reactive" Biliary Epithelial Phenotype 245
The challenges of primary biliary cholangitis: What is new and what needs to be done 245
Functional anatomy of normal bile ducts 243
Effect of age on single- and multiple-dose pharmacokinetics of erythromycin 243
Foxa1 and Foxa2 regulate bile duct development in mice 243
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling 242
The cholangiopathies: disorders of biliary epithelia 242
Continuous subcutaneous insulin infusion in Italy: Third national survey 242
Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19 241
Cholangiocyte pathobiology 240
Effect of Silybin on biliary lipid composition in rats 239
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 238
Intracellular alkalinization stimulates bile flow and vesicular-mediated exocytosis in IPRL 237
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 237
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 237
JNK SIGNALING ACTIVATED BY PLATELET-DERIVED GROWTH FACTOR D (PDGF-D) STIMULATES SECRETION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C) BY CANCER-ASSOCIATED FIBROBLASTS TO PROMOTE LYMPHANGIOGENESIS AND EARLY METASTASIZATION IN CHOLANGIOCARCINOMA 236
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib 236
"The city of Hepar": Rituals, gastronomy, and politics at the origins of the modern names for the liver 236
Β-Catenin-Mediated Cxcl1 and Cxcl10 Secretion by Fibrocystin-Defective Cholangiocytes Regulates Peribiliary Recruitment of Fibrocytes in Congenital Hepatic Fibrosis 236
Monocyte/macrophage peribiliary recruitment by pkhd1-defective cholangiocytes induces expression of avb6 integrin on biliary cysts via tgf-β1 and tnf-α in congenital hepatic fibrosis 236
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 234
Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview 233
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice 232
Sorafenib paradoxically activates the raf/mek/erk signaling in mice with polycystic liver disease (pld) caused by conditional deletion of polycystin-2 232
Pka-dependent p-ser-675-catenin phosphorylation increases cholangiocyte motility in a mouse model of fibropolycystic liver diseases 232
Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. 229
Notch signaling and new therapeutic options in liver disease 229
Animal models of cholestasis: An update on inflammatory cholangiopathies 229
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 228
Notch signaling and progenitor/ductular reaction in steatohepatitis 228
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 228
Intracellular pH regulation in isolated rat bile duct epithelial cells 226
Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line 225
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 224
Altered store operated calcium entry increases cAMP production and ERK1/2 phosphorylation in Polycystin-2 defective cholangiocytes 224
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 224
Effect of UDCA on intracellular and biliary pH in isolated rat hepatocyte couplets and perfused livers 223
Totale 27.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.011 0 0 0 0 0 0 0 0 0 434 274 303
2021/20222.877 130 293 499 219 101 210 133 197 143 199 244 509
2022/20235.338 594 1.602 470 404 435 810 72 278 369 31 178 95
2023/20243.783 151 142 112 179 505 1.038 764 139 333 33 24 363
2024/20258.323 551 1.073 423 324 775 275 522 405 757 1.178 652 1.388
2025/202617.304 2.210 1.393 1.359 1.726 2.090 1.183 2.554 1.068 1.823 1.898 0 0
Totale 57.985